The β-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases

Progress in Retinal and Eye Research

Volumn 42, Issue , 2014, Pages 103-129

  Casini, Giovanni ^a   Dal Monte, Massimo ^a   Fornaciari, Irene ^a   Filippi, Luca ^b   Bagnoli, Paola ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Angiogenesis; Neuroprotection; Oxygen induced retinopathy model; Preterm infants; AR blockade; 1 2 AR knock out mice

Indexed keywords

ANGIOGENIC FACTOR; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ISOPRENALINE; OXYGEN; PROPRANOLOL; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; APOPTOSIS; BETA ADRENERGIC RECEPTOR BLOCKING; CELL SURVIVAL; CELL VIABILITY; DIABETIC RETINOPATHY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; MOUSE MODEL; NERVE CELL; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; OXYGEN-INDUCED RETINOPATHY; PREMATURITY; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REDUCTION; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETINA NERVE CELL; RETROLENTAL FIBROPLASIA; REVIEW; SIGNAL TRANSDUCTION; SUBRETINAL NEOVASCULARIZATION; THROMBOEMBOLISM; TISSUE DISTRIBUTION; ANIMAL; DRUG EFFECTS; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; RETINA; RETINAL DISEASES; RETINAL NEOVASCULARIZATION;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; APOPTOSIS; HUMANS; MICE; RATS; RECEPTORS, ADRENERGIC, BETA; RETINA; RETINAL DISEASES; RETINAL NEOVASCULARIZATION;

EID: 84906046900     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2014.06.001     Document Type: Review

References (287)

1. Adams A.J., Bearse M.A. Retinal neuropathy precedes vasculopathy in diabetes: a function-based opportunity for early treatment intervention?. Clin. Exp. Optom. 2012, 95:256-265.
2. Adelman R.A., Zheng Q., Mayer H.R. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J.Ocul. Pharmacol. Ther. 2010, 26:105-110.
3. Afzal A., Shaw L.C., Ljubimov A.V., Boulton M.E., Segal M.S., Grant M.B. Retinal and choroidal microangiopathies: therapeutic opportunities. Microvasc. Res. 2007, 74:131-144.
4. Akula J.D., Hansen R.M., Martinez-Perez M.E., Fulton A.B. Rod photoreceptor function predicts blood vessel abnormality in retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2007, 48:4351-4359.
5. Al-Wadei H.A., Al-Wadei M.H., Schuller H.M. Prevention of pancreatic cancer by the beta-blocker propranolol. Anticancer. Drugs 2009, 20:477-482.
6. Amadio M., Bucolo C., Leggio G.M., Drago F., Govoni S., Pascale A. The PKCbeta/HuR/VEGF pathway in diabetic retinopathy. Biochem. Pharmacol. 2010, 80:1230-1237.
7. Antonetti D.A., Klein R., Gardner T.W. Diabetic retinopathy. N.Engl. J. Med. 2012, 366:1227-1239.
8. Arai K., Wood J.P., Osborne N.N. Beta-adrenergic receptor agonists and antagonists counteract LPS-induced neuronal death in retinal cultures by different mechanisms. Brain Res. 2003, 985:176-186.
9. Arjamaa O., Nikinmaa M. Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp. Eye Res. 2006, 83:473-483.
10. Azzouz M., Ralph G.S., Storkebaum E., Walmsley L.E., Mitrophanous K.A., Kingsman S.M., Carmeliet P., Mazarakis N.D. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004, 429:413-417.
11. Baird A., Esch F., Gospodarowicz D., Guillemin R. Retina- and eye-derived endothelial cell growth factors: partial molecular characterization and identity with acidic and basic fibroblast growth factors. Biochem. (Mosc) 1985, 24:7855-7860.
12. Baker J.G. The selectivity of β-adrenoceptor agonists at human β1-, β2- and β3-adrenoceptors. Br. J. Pharmacol. 2010, 160:1048-1061.
13. Balligand J.L. Beta3-adrenoreceptors in cardiovasular diseases: new roles for an "old" receptor. Curr. Drug. Deliv. 2013, 10:64-66.
14. Barber A.J. Anew view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:283-290.
15. Barber A.J., Lieth E., Khin S.A., Antonetti D.A., Buchanan A.G., Gardner T.W. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J.Clin. Invest. 1998, 102:783-791.
16. Behl Y., Krothapalli P., Desta T., DiPiazza A., Roy S., Graves D.T. Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am. J. Pathol. 2008, 172:1411-1418.
17. Bek T. Glial cell involvement in vascular occlusion of diabetic retinopathy. Acta Ophthalmol. Scand. 1997, 75:239-243.
18. Bloch S.B., Larsen M., Munch I.C. Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010. Am. J. Ophthalmol. 2012, 153:209-213. e202.
19. Brockington A., Heath P.R., Holden H., Kasher P., Bender F.L., Claes F., Lambrechts D., Sendtner M., Carmeliet P., Shaw P.J. Downregulation of genes with a function in axon outgrowth and synapse formation in motor neurones of the VEGFdelta/delta mouse model of amyotrophic lateral sclerosis. BMC Genom. 2010, 11:203.
20. Brown D.M., Michels M., Kaiser P.K., Heier J.S., Sy J.P., Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009, 116:57-65. e55.
21. Bruinink A., Dawis S., Niemeyer G., Lichtensteiger W. Catecholaminergic binding sites in cat retina, pigment epithelium and choroid. Exp. Eye Res. 1986, 43:147-151.
22. Campochiaro P.A. Ocular neovascularization. J.Mol. Med. Berl. 2013, 91:311-321.
23. Campochiaro P.A., Nguyen Q.D., Shah S.M., Klein M.L., Holz E., Frank R.N., Saperstein D.A., Gupta A., Stout J.T., Macko J., DiBartolomeo R., Wei L.L. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum. Gene Ther. 2006, 17:167-176.
24. Cernecka H., Ochodnicky P., Lamers W.H., Michel M.C. Specificity evaluation of antibodies against human β3-adrenoceptors. Naunyn Schmiedeb. Arch. Pharmacol. 2012, 385:875-882.
25. Cervia D., Catalani E., Dal Monte M., Casini G. Vascular endothelial growth factor in the ischemic retina and its regulation by somatostatin. J.Neurochem. 2012, 120:818-829.
26. Cervia D., Martini D., Ristori C., Catalani E., Timperio A.M., Bagnoli P., Casini G. Modulation of the neuronal response to ischaemia by somatostatin analogues in wild-type and knock-out mouse retinas. J.Neurochem. 2008, 106:2224-2235.
27. Chandel N.S., Maltepe E., Goldwasser E., Mathieu C.E., Simon M.C., Schumacker P.T. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:11715-11720.
28. 2 sensing. J.Biol. Chem. 2000, 275:25130-25138.
29. Chandrasekera P.C., Wan T.C., Gizewski E.T., Auchampach J.A., Lasley R.D. Adenosine A1 receptors heterodimerize with beta1- and beta2-adrenergic receptors creating novel receptor complexes with altered G protein coupling and signaling. Cell. Signal 2013, 25:736-742.
30. Chen J., Joyal J.S., Hatton C.J., Juan A.M., Pei D.T., Hurst C.G., Xu D., Stahl A., Hellström A., Smith L.E. Propranolol inhibition of beta-adrenergic receptor does not suppress pathologic neovascularization in oxygen-induced retinopathy. Invest. Ophthalmol. Vis. Sci. 2012, 53:2968-2977.
31. Chen J., Hellström A., Smith L.E. Author response: different efficacy of propranolol in mice with oxygen-induced retinopathy: could differential effects of propranolol be related to differences in mouse strains?. Invest. Ophthalmol. Vis. Sci. 2012, 53:7728-7729.
32. Chen J., Smith L.E. Retinopathy of prematurity. Angiogenesis 2007, 10:133-140.
33. Chen X.Q., Du J.Z., Wang Y.S. Regulation of hypoxia-induced release of corticotropin-releasing factor in the rat hypothalamus by norepinephrine. Regul. Pept. 2004, 119:221-228.
34. Chen Z., Jia W., Kaufman P.L., Cynader M. Immunohistochemical localization of dopamine-beta-hydroxylase in human and monkey eyes. Curr. Eye Res. 1999, 18:39-48.
35. Cheon E.W., Park C.H., Kang S.S., Cho G.J., Yoo J.M., Song J.K., Choi W.S. Nitric oxide synthase expression in the transient ischemic rat retina: neuroprotection of betaxolol. Neurosci. Lett. 2002, 330:265-269.
36. Cheon E.W., Park C.H., Kang S.S., Cho G.J., Yoo J.M., Song J.K., Choi W.S. Betaxolol attenuates retinal ischemia/reperfusion damage in the rat. Neuroreport 2003, 14:1913-1917.
37. Cheung N., Mitchell P., Wong T.Y. Diabetic retinopathy. Lancet 2010, 376:124-136.
38. Chidlow G., Melena J., Osborne N.N. Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists. Br. J. Pharmacol. 2000, 130:759-766.
39. Chim H., Armijo B.S., Miller E., Gliniak C., Serret M.A., Gosain A.K. Propranolol induces regression of hemangioma cells through HIF-1alpha-mediated inhibition of VEGF-A. Ann. Surg. 2012, 256:146-156.
40. Conti V., Russomanno G., Corbi G., Izzo V., Vecchione C., Filippelli A. Adrenoreceptors and nitric oxide in the cardiovascular system. Front. Physiol. 2013, 4:321.
41. Counts S.E., Mufson E.J. Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity. J.Neurochem 2010, 113:649-660.
42. Culmsee C., Junker V., Kremers W., Thal S., Plesnila N., Krieglstein J. Combination therapy in ischemic stroke: synergistic neuroprotective effects of memantine and clenbuterol. Stroke 2004, 35:1197-1202.
43. Culmsee C., Semkova I., Krieglstein J. NGF mediates the neuroprotective effect of the beta2-adrenoceptor agonist clenbuterol invitro and invivo: evidence from an NGF-antisense study. Neurochem. Int. 1999, 35:47-57.
44. Culmsee C., Stumm R.K., Schafer M.K., Weihe E., Krieglstein J. Clenbuterol induces growth factor mRNA, activates astrocytes, and protects rat brain tissue against ischemic damage. Eur. J. Pharmacol. 1999, 379:33-45.
45. Dal Monte M., Cammalleri M., Martini D., Casini G., Bagnoli P. Antiangiogenic role of somatostatin receptor 2 in a model of hypoxia-induced neovascularization in the retina: results from transgenic mice. Invest. Ophthalmol. Vis. Sci. 2007, 48:3480-3489.
46. Dal Monte M., Filippi L., Bagnoli P. Beta3-adrenergic receptors modulate vascular endothelial growth factor release in response to hypoxia through the nitric oxide pathway in mouse retinal explants. Naunyn Schmiedeb. Arch. Pharmacol. 2013, 386:269-278.
47. Dal Monte M., Casini G., la Marca G., Isacchi B., Filippi L., Bagnoli P. Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice. Exp. Eye Res. 2013, 111:27-35.
48. Dal Monte M., Martini D., Latina V., Pavan B., Filippi L., Bagnoli P. Beta-adrenoreceptor agonism influences retinal responses to hypoxia in a model of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2012, 53:2181-2192.
49. 2+ channel Cav1.2. Science 2001, 293:98-101.
50. Davies M.H., Zamora D.O., Smith J.R., Powers M.R. Soluble ephrin-B2 mediates apoptosis in retinal neovascularization and in endothelial cells. Microvasc. Res. 2009, 77:382-386.
51. Davis A., Cohen S.M., Pautler S.E., Billiris-Findlay K., Eichenbaum D.A. Beta blocker use and age-related macular degeneration. Acta Ophthalmol. 2012, 90:e162-e163.
52. Deissler H., Lang S., Lang G.E. VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells. Br. J. Ophthalmol. 2008, 92:839-843.
53. Delaey C., Van De Voorde J. Regulatory mechanisms in the retinal and choroidal circulation. Ophthalmic Res. 2000, 32:249-256.
54. Do D.V., Nguyen Q.D., Boyer D., Schmidt-Erfurth U., Brown D.M., Vitti R., Berliner A.J., Gao B., Zeitz O., Ruckert R., Schmelter T., Sandbrink R., Heier J.S. One-year outcomes of the da Vinci Study of VEGF trap-eye in eyes with diabetic macular edema. Ophthalmology 2012, 119:1658-1665.
55. Downie L.E., Pianta M.J., Vingrys A.J., Wilkinson-Berka J.L., Fletcher E.L. Neuronal and glial cell changes are determined by retinal vascularization in retinopathy of prematurity. J.Comp. Neurol. 2007, 504:404-417.
56. Drolet B.A., Frieden I.J. Characteristics of infantile hemangiomas as clues to pathogenesis: does hypoxia connect the dots?. Arch. Dermatol. 2010, 146:1295-1299.
57. Drolet B.A., Swanson E.A., Frieden I.J. Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants. J.Pediatr. 2008, 153:712-715.
58. Early Treatment For Retinopathy Of Prematurity Cooperative Group Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch. Ophthalmol. 2003, 121:1684-1694.
59. Edelman J.L., Lutz D., Castro M.R. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp. Eye Res. 2005, 80:249-258.
60. Eichler W., Kuhrt H., Hoffmann S., Wiedemann P., Reichenbach A. VEGF release by retinal glia depends on both oxygen and glucose supply. Neuroreport 2000, 11:3533-3537.
61. Elena P.P., Denis P., Kosina-Boix M., Saraux H., Lapalus P. Beta adrenergic binding sites in the human eye: an autoradiographic study. J.Ocul. Pharmacol. 1990, 6:143-149.
62. Elena P.P., Kosina-Boix M., Moulin G., Lapalus P. Autoradiographic localization of beta-adrenergic receptors in rabbit eye. Invest. Ophthalmol. Vis. Sci. 1987, 28:1436-1441.
63. Erickson K.K., Sundstrom J.M., Antonetti D.A. Vascular permeability in ocular disease and the role of tight junctions. Angiogenesis 2007, 10:103-117.
64. Falavarjani K.G., Nguyen Q.D. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond) 2013, 27:787-794.
65. Famiglietti E.V., Stopa E.G., McGookin E.D., Song P., LeBlanc V., Streeten B.W. Immunocytochemical localization of vascular endothelial growth factor in neurons and glial cells of human retina. Brain Res. 2003, 969:195-204.
66. Favaloro E.J., Moraitis N., Koutts J., Exner T., Bradstock K.F. Endothelial cells and normal circulating haemopoietic cells share a number of surface antigens. Thromb. Haemost. 1989, 61:217-224.
67. Ferrari-Dileo G. Beta 1 and beta 2 adrenergic binding sites in bovine retina and retinal blood vessels. Invest. Ophthalmol. Vis. Sci. 1988, 29:695-699.
68. Ferrari-Dileo G., Davis E.B., Anderson D.R. Effects of cholinergic and adrenergic agonists on adenylate cyclase activity of retinal microvascular pericytes in culture. Invest. Ophthalmol. Vis. Sci. 1992, 33:42-47.
69. Filippi L., Cavallaro G., Fiorini P., Malvagia S., Della Bona M.L., Giocaliere E., Bagnoli P., Dal Monte M., Mosca F., Donzelli G., la Marca G. Propranolol concentrations after oral administration in term and preterm neonates. J.Matern. Fetal Neonatal Med. 2013, 26:833-840.
70. Filippi L., Cavallaro G., Bagnoli P., Dal Monte M., Fiorini P., Donzelli G., Tinelli F., Araimo G., Cristofori G., la Marca G., Della Bona M.L., La Torre A., Fortunato P., Furlanetto S., Osnaghi S., Mosca F. Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. J.Pediatr. 2013, 163:1570-1577. e1576.
71. Filippi L., Cavallaro G., Fiorini P., Daniotti M., Benedetti V., Cristofori G., Araimo G., Ramenghi L., La Torre A., Fortunato P., Pollazzi L., la Marca G., Malvagia S., Bagnoli P., Ristori C., Dal Monte M., Bilia A.R., Isacchi B., Furlanetto S., Tinelli F., Cioni G., Donzelli G., Osnaghi S., Mosca F. Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491. BMC Pediatr. 2010, 10:83.
72. Filippi L., Dal Monte M., Bagnoli P. Different efficacy of propranolol in mice with oxygen-induced retinopathy: could differential effects of propranolol be related to differences in mouse strains?. Invest. Ophthalmol. Vis. Sci. 2012, 53:7421-7423.
73. Fleck B.W. Management of retinopathy of prematurity. Arch. Dis. Child. Fetal Neonatal Ed. 2013, 98:F454-F456.
74. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N.Engl. J. Med. 1995, 333:1757-1763.
75. Follesa P., Mocchetti I. Regulation of basic fibroblast growth factor and nerve growth factor mRNA by beta-adrenergic receptor activation and adrenal steroids in rat central nervous system. Mol. Pharmacol. 1993, 43:132-138.
76. Foxton R.H., Finkelstein A., Vijay S., Dahlmann-Noor A., Khaw P.T., Morgan J.E., Shima D.T., Ng Y.S. VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma. Am. J. Pathol. 2013, 182:1379-1390.
77. Fredriksson J.M., Lindquist J.M., Bronnikov G.E., Nedergaard J. Norepinephrine induces vascular endothelial growth factor gene expression in brown adipocytes through a beta -adrenoreceptor/cAMP/protein kinase A pathway involving Src but independently of Erk1/2. J.Biol. Chem. 2000, 275:13802-13811.
78. Fruttiger M. Development of the retinal vasculature. Angiogenesis 2007, 10:77-88.
79. Fukuda M., Ishimoto I., Kuwayama Y., Shimizu Y., Shiosaka S., Takagi H., Tohyama M. Monoamine accumulating neuron system in the rat retina with special reference to noradrenaline accumulating neurons. Exp. Eye Res. 1982, 34:487-491.
80. Fulton A.B., Hansen R.M., Moskowitz A., Akula J.D. The neurovascular retina in retinopathy of prematurity. Prog. Retin. Eye Res. 2009, 28:452-482.
81. Fulton A.B., Hansen R.M., Moskowitz A., Barnaby A.M. Multifocal ERG in subjects with a history of retinopathy of prematurity. Doc. Ophthalmol. 2005, 111:7-13.
82. Gagnon A.W., Kallal L., Benovic J.L. Role of clathrin-mediated endocytosis in agonist-induced down-regulation of the beta2-adrenergic receptor. J.Biol. Chem. 1998, 273:6976-6981.
83. Gambarana C., Ordway G.A., Hauptmann M., Tejani-Butt S., Frazer A. Central administration of 1-isoproterenol invivo induces a preferential regulation of beta 2-adrenoceptors in the central nervous system of the rat. Brain Res. 1991, 555:141-148.
84. Gergely K., Gerinec A. Retinopathy of prematurity-epidemics, incidence, prevalence, blindness. Bratisl. Lek. Listy 2010, 111:514-517.
85. Gloerich M., Bos J.L. Epac: defining a new mechanism for cAMP action. Annu. Rev. Pharmacol. Toxicol. 2010, 50:355-375.
86. Gomes E., Papa L., Hao T., Rockwell P. The VEGFR2 and PKA pathways converge at MEK/ERK1/2 to promote survival in serum deprived neuronal cells. Mol. Cell. Biochem. 2007, 305:179-190.
87. Goto W., Ota T., Morikawa N., Otori Y., Hara H., Kawazu K., Miyawaki N., Tano Y. Protective effects of timolol against the neuronal damage induced by glutamate and ischemia in the rat retina. Brain Res. 2002, 958:10-19.
88. Greene D., Kang S., Kosenko A., Hoshi N. Adrenergic regulation of HCN4 channel requires protein association with beta2-adrenergic receptor. J.Biol. Chem. 2012, 287:23690-23697.
89. Grossniklaus H.E., Kang S.J., Berglin L. Animal models of choroidal and retinal neovascularization. Prog. Retin. Eye Res. 2010, 29:500-519.
90. Gupta N., Mansoor S., Sharma A., Sapkal A., Sheth J., Falatoonzadeh P., Kuppermann B., Kenney M. Diabetic retinopathy and VEGF. Open. Ophthalmol. J. 2013, 7:4-10.
91. Haack K.K., Tougas M.R., Jones K.T., El-Dahr S.S., Radhakrishna H., McCarty N.A. Anovel bioassay for detecting GPCR heterodimerization: transactivation of beta 2 adrenergic receptor by bradykinin receptor. J.Biomol. Screen 2010, 15:251-260.
92. Hadjiconstantinou M., Cohen J., Neff N.H. Epinephrine: a potential neurotransmitter in retina. J.Neurochem. 1983, 41:1440-1444.
93. Hadjiconstantinou M., Mariani A.P., Panula P., Joh T.H., Neff N.H. Immunohistochemical evidence for epinephrine-containing retinal amacrine cells. Neuroscience 1984, 13:547-551.
94. Hamdani N., van der Velden J. Lack of specificity of antibodies directed against human beta-adrenergic receptors. Naunyn Schmiedeb. Arch. Pharmacol. 2009, 379:403-407.
95. Haggstrom A.N., Lammer E.J., Schneider R.A., Marcucio R., Frieden I.J. Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development. Pediatrics 2006, 117:698-703.
96. Hall R.A. Beta-adrenergic receptors and their interacting proteins. Semin. Cell. Dev. Biol. 2004, 15:281-288.
97. Hammer D.X., Iftimia N.V., Ferguson R.D., Bigelow C.E., Ustun T.E., Barnaby A.M., Fulton A.B. Foveal fine structure in retinopathy of prematurity: an adaptive optics Fourier domain optical coherence tomography study. Invest. Ophthalmol. Vis. Sci. 2008, 49:2061-2070.
98. Han Y., Wu S.M. NMDA-evoked [Ca2+]i increase in salamander retinal ganglion cells: modulation by PKA and adrenergic receptors. Vis. Neurosci. 2002, 19:249-256.
99. Hanout M., Ferraz D., Ansari M., Maqsood N., Kherani S., Sepah Y.J., Rajagopalan N., Ibrahim M., Do D.V., Nguyen Q.D. Therapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in development. Biomed. Res. Int. 2013, 2013:830837.
100. Hansen J.L., Theilade J., Aplin M., Sheikh S.P. Role of G-protein-coupled receptor kinase 2 in the heart-do regulatory mechanisms open novel therapeutic perspectives?. Trends Cardiovasc. Med. 2006, 16:169-177.
101. Hayes V.Y., Isackson P.J., Fabrazzo M., Follesa P., Mocchetti I. Induction of nerve growth factor and basic fibroblast growth factor mRNA following clenbuterol: contrasting anatomical and cellular localization. Exp. Neurol. 1995, 132:33-41.
102. Hayreh S.S. Neovascular glaucoma. Prog. Retin. Eye Res. 2007, 26:470-485.
103. Hellström A., Smith L.E., Dammann O. Retinopathy of prematurity. Lancet 2013, 382:1445-1457.
104. Hernandez C., Simo R. Neuroprotection in diabetic retinopathy. Curr. Diab Rep. 2012, 12:329-337.
105. Hirooka K., Kelly M.E., Baldridge W.H., Barnes S. Suppressive actions of betaxolol on ionic currents in retinal ganglion cells may explain its neuroprotective effects. Exp. Eye Res. 2000, 70:611-621.
106. Hodis J., Vaclavikova R., Farghali H. Beta-3 agonist-induced lipolysis and nitric oxide production: relationship to PPARgamma agonist/antagonist and AMP kinase modulation. Gen. Physiol. Biophys. 2011, 30:90-99.
107. Hoffmann C., Leitz M.R., Oberdorf-Maass S., Lohse M.J., Klotz K.N. Comparative pharmacology of human beta-adrenergic receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn Schmiedeb. Arch. Pharmacol. 2004, 369:151-159.
108. Holopigian K., Seiple W., Lorenzo M., Carr R. Acomparison of photopic and scotopic electroretinographic changes in early diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 1992, 33:2773-2780.
109. 2+ channel-blocking activity of propranolol and betaxolol in isolated bovine retinal microartery. J.Cardiovasc. Pharmacol. 1998, 32:390-396.
110. Hunter A.J. Calcium antagonists: their role in neuroprotection. Int. Rev. Neurobiol. 1997, 40:95-108.
111. Iaccarino G., Ciccarelli M., Sorriento D., Galasso G., Campanile A., Santulli G., Cipolletta E., Cerullo V., Cimini V., Altobelli G.G., Piscione F., Priante O., Pastore L., Chiariello M., Salvatore F., Koch W.J., Trimarco B. Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system. Circ. Res. 2005, 97:1182-1189.
112. Ignarro L.J., Sisodia M., Trinh K., Bedrood S., Wu G., Wei L.H., Buga G.M. Nebivolol inhibits vascular smooth muscle cell proliferation by mechanisms involving nitric oxide but not cyclic GMP. Nitric Oxide 2002, 7:83-90.
113. Ishida S., Usui T., Yamashiro K., Kaji Y., Ahmed E., Carrasquillo K.G., Amano S., Hida T., Oguchi Y., Adamis A.P. VEGF164 is proinflammatory in the diabetic retina. Invest. Ophthalmol. Vis. Sci. 2003, 44:2155-2162.
114. Ji Y., Chen S., Li K., Li L., Xu C., Xiang B. Signaling pathways in the development of infantile hemangioma. J.Hematol. Oncol. 2014, 7:13.
115. Ji Y., Li K., Xiao X., Zheng S., Xu T., Chen S. Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells. J.Pediatr. Surg. 2012, 47:2216-2223.
116. Jiang Y., Zhang Q., Liu L., Tang J., Kern T.S., Steinle J.J. beta2-adrenergic receptor knockout mice exhibit A diabetic retinopathy phenotype. PLoS One 2013, 8:e70555.
117. Jiang Y., Liu L., Pagadala J., Miller D.D., Steinle J.J. Compound 49b protects against blast-induced retinal injury. J.Neuroinflam. 2013, 10:96.
118. Jiang Y., Pagadala J., Miller D., Steinle J.J. Reduced insulin receptor signaling in retinal Muller cells cultured in high glucose. Mol. Vis. 2013, 19:804-811.
119. Jiang Y., Steinle J.J. Systemic propranolol reduces b-wave amplitude in the ERG and increases IGF-1 receptor phosphorylation in rat retina. Invest. Ophthalmol. Vis. Sci. 2010, 51:2730-2735.
120. Jiang Y., Walker R.J., Kern T.S., Steinle J.J. Application of isoproterenol inhibits diabetic-like changes in the rat retina. Exp. Eye Res. 2010, 91:171-179.
121. Jin K.L., Mao X.O., Greenberg D.A. Vascular endothelial growth factor: direct neuroprotective effect in invitro ischemia. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:10242-10247.
122. Joussen A.M., Doehmen S., Le M.L., Koizumi K., Radetzky S., Krohne T.U., Poulaki V., Semkova I., Kociok N. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol. Vis. 2009, 15:1418-1428.
123. Junker V., Becker A., Huhne R., Zembatov M., Ravati A., Culmsee C., Krieglstein J. Stimulation of beta-adrenoceptors activates astrocytes and provides neuroprotection. Eur. J. Pharmacol. 2002, 446:25-36.
124. Kahle G., Kaulen P., Wollensak J. Quantitative autoradiography of beta-adrenergic receptors in rabbit eyes. Exp. Eye Res. 1990, 51:503-507.
125. Kaiser P.K. Emerging therapies for neovascular age-related macular degeneration: drugs in the pipeline. Ophthalmology 2013, 120:S11-S15.
126. Katritch V., Reynolds K.A., Cherezov V., Hanson M.A., Roth C.B., Yeager M., Abagyan R. Analysis of full and partial agonists binding to beta2-adrenergic receptor suggests a role of transmembrane helix V in agonist-specific conformational changes. J.Mol. Recognit. 2009, 22:307-318.
127. Kaur C., Foulds W.S., Ling E.A. Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog. Retin. Eye Res. 2008, 27:622-647.
128. Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J., Connolly D.T. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989, 246:1309-1312.
129. Kelley C., D'Amore P., Hechtman H.B., Shepro D. Microvascular pericyte contractility invitro: comparison with other cells of the vascular wall. J.Cell. Biol. 1987, 104:483-490.
130. Kilic U., Kilic E., Jarve A., Guo Z., Spudich A., Bieber K., Barzena U., Bassetti C.L., Marti H.H., Hermann D.M. Human vascular endothelial growth factor protects axotomized retinal ganglion cells invivo by activating ERK-1/2 and Akt pathways. J.Neurosci. 2006, 26:12439-12446.
131. Kleinman M.E., Greives M.R., Churgin S.S., Blechman K.M., Chang E.I., Ceradini D.J., Tepper O.M., Gurtner G.C. Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2664-2670.
132. Kobayashi T., Mori Y. Ca2+ channel antagonists and neuroprotection from cerebral ischemia. Eur. J. Pharmacol. 1998, 363:1-15.
133. Kohzaki K., Vingrys A.J., Bui B.V. Early inner retinal dysfunction in streptozotocin-induced diabetic rats. Invest. Ophthalmol. Vis. Sci. 2008, 49:3595-3604.
134. Korhonen R., Korpela R., Moilanen E. Signalling mechanisms involved in the induction of inducible nitric oxide synthase by Lactobacillus rhamnosus GG, endotoxin, and lipoteichoic acid. Inflammation 2002, 26:207-214.
135. Krasel C., Bunemann M., Lorenz K., Lohse M.J. Beta-arrestin binding to the beta2-adrenergic receptor requires both receptor phosphorylation and receptor activation. J.Biol. Chem. 2005, 280:9528-9535.
136. Krishnan R., Goverdhan S., Lochhead J. Submacular haemorrhage after intravitreal bevacizumab compared with intravitreal ranibizumab in large occult choroidal neovascularization. Clin. Exp. Ophthalmol. 2009, 37:384-388.
137. Kvanta A. Expression and regulation of vascular endothelial growth factor in choroidal fibroblasts. Curr. Eye Res. 1995, 14:1015-1020.
138. Lamy S., Lachambre M.P., Lord-Dufour S., Beliveau R. Propranolol suppresses angiogenesis invitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vasc. Pharmacol. 2010, 53:200-208.
139. Lashbrook B.L., Steinle J.J. Beta-adrenergic receptor regulation of pigment epithelial-derived factor expression in rat retina. Auton. Neurosci. 2005, 121:33-39.
140. Lavine J.A., Sang Y., Wang S., Ip M.S., Sheibani N. Attenuation of choroidal neovascularization by beta(2)-adrenoreceptor antagonism. JAMA Ophthalmol. 2013, 131:376-382.
141. Lavoie C., Mercier J.F., Salahpour A., Umapathy D., Breit A., Villeneuve L.R., Zhu W.Z., Xiao R.P., Lakatta E.G., Bouvier M., Hebert T.E. Beta 1/beta 2-adrenergic receptor heterodimerization regulates beta 2-adrenergic receptor internalization and ERK signaling efficacy. J.Biol. Chem. 2002, 277:35402-35410.
142. Leaute-Labreze C., Dumas de la Roque E., Hubiche T., Boralevi F., Thambo J.B., Taieb A. Propranolol for severe hemangiomas of infancy. N.Engl. J. Med. 2008, 358:2649-2651.
143. Li Q., Zemel E., Miller B., Perlman I. Early retinal damage in experimental diabetes: electroretinographical and morphological observations. Exp. Eye Res. 2002, 74:615-625.
144. Liang X., Zhou H., Ding Y., Li J., Yang C., Luo Y., Li S., Sun G., Liao X., Min W. TMP prevents retinal neovascularization and imparts neuroprotection in an oxygen-induced retinopathy model. Invest. Ophthalmol. Vis. Sci. 2012, 53:2157-2169.
145. Lindgren I., Altimiras J. Chronic prenatal hypoxia sensitizes beta-adrenoceptors in the embryonic heart but causes postnatal desensitization. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 297:R258-R264.
146. Liu X., Chen H.H., Zhang L.W. Potential therapeutic effects of pigment epithelium-derived factor for treatment of diabetic retinopathy. Int. J. Ophthalmol. 2013, 6:221-227.
147. Lu H., Dalgard C.L., Mohyeldin A., McFate T., Tait A.S., Verma A. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J.Biol. Chem. 2005, 280:41928-41939.
148. Lutgendorf S.K., Cole S., Costanzo E., Bradley S., Coffin J., Jabbari S., Rainwater K., Ritchie J.M., Yang M., Sood A.K. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin. Cancer Res. 2003, 9:4514-4521.
149. Mackenzie F., Ruhrberg C. Diverse roles for VEGF-A in the nervous system. Development 2012, 139:1371-1380.
150. Madrigal J.L., Kalinin S., Richardson J.C., Feinstein D.L. Neuroprotective actions of noradrenaline: effects on glutathione synthesis and activation of peroxisome proliferator activated receptor delta. J.Neurochem. 2007, 103:2092-2101.
151. Madrigal J.L., Leza J.C., Polak P., Kalinin S., Feinstein D.L. Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline. J.Neurosci. 2009, 29:263-267.
152. Malik F.Y., Nassar C.F., Saadeh N.E., Shammas N.W., Jabbur S.J. Dopaminergic and adrenergic binding affinities in rabbit retinal synaptosomes. Gen. Pharmacol. 1988, 19:735-739.
153. Martini D., Monte M.D., Ristori C., Cupisti E., Mei S., Fiorini P., Filippi L., Bagnoli P. Antiangiogenic effects of beta2 -adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy. J.Neurochem. 2011, 119:1317-1329.
154. Massion P.B., Dessy C., Desjardins F., Pelat M., Havaux X., Belge C., Moulin P., Guiot Y., Feron O., Janssens S., Balligand J.L. Cardiomyocyte-restricted overexpression of endothelial nitric oxide synthase (NOS3) attenuates beta-adrenergic stimulation and reinforces vagal inhibition of cardiac contraction. Circulation 2004, 110:2666-2672.
155. Masuzawa K., Jesmin S., Maeda S., Zaedi S., Shimojo N., Miyauchi T., Goto K. Effect of endothelin dual receptor antagonist on VEGF levels in streptozotocin-induced diabetic rat retina. Exp. Biol. Med. (Maywood) 2006, 231:1090-1094.
156. Mei S., Cammalleri M., Azara D., Casini G., Bagnoli P., Dal Monte M. Mechanisms underlying somatostatin receptor 2 down-regulation of vascular endothelial growth factor expression in response to hypoxia in mouse retinal explants. J. Pathol 2012, 226:519-533.
157. Melena J., Stanton D., Osborne N.N. Comparative effects of antiglaucoma drugs on voltage-dependent calcium channels. Graefes Arch. Clin. Exp. Ophthalmol. 2001, 239:522-530.
158. 2+ channels. Eur. J. Pharmacol. 1999, 378:317-322.
159. Mercier J.F., Salahpour A., Angers S., Breit A., Bouvier M. Quantitative assessment of beta 1- and beta 2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer. J.Biol. Chem. 2002, 277:44925-44931.
160. Meyer-Rüsenberg B., Pavlidis M., Stupp T., Thanos S. Pathological changes in human retinal ganglion cells associated with diabetic and hypertensive retinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2007, 245:1009-1018.
161. Miller H., Miller B., Ishibashi T., Ryan S.J. Pathogenesis of laser-induced choroidal subretinal neovascularization. Invest. Ophthalmol. Vis. Sci. 1990, 31:899-908.
162. Mizutani M., Gerhardinger C., Lorenzi M. Muller cell changes in human diabetic retinopathy. Diabetes 1998, 47:445-449.
163. Montero J.A., Ruiz-Moreno J.M., Sanchis-Merino E., Perez-Martin S. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab. Retina 2013, 33:508-512.
164. Mordenti J., Cuthbertson R.A., Ferrara N., Thomsen K., Berleau L., Licko V., Allen P.C., Valverde C.R., Meng Y.G., Fei D.T., Fourre K.M., Ryan A.M. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol. Pathol. 1999, 27:536-544.
165. Mori A., Miwa T., Sakamoto K., Nakahara T., Ishii K. Pharmacological evidence for the presence of functional beta(3)-adrenoceptors in rat retinal blood vessels. Naunyn Schmiedeb. Arch. Pharmacol. 2010, 382:119-126.
166. Mori K., Duh E., Gehlbach P., Ando A., Takahashi K., Pearlman J., Yang H.S., Zack D.J., Ettyreddy D., Brough D.E., Wei L.L., Campochiaro P.A. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J.Cell. Physiol. 2001, 188:253-263.
167. Moschos M., Panagakis E., Angelopoulos A. Changes of oscillatory potentials of the ERG in diabetic retinopathy. Ophthalmic Physiol. Opt. 1987, 7:477-479.
168. Narayanan S.P., Suwanpradid J., Saul A., Xu Z., Still A., Caldwell R.W., Caldwell R.B. Arginase 2 deletion reduces neuro-glial injury and improves retinal function in a model of retinopathy of prematurity. PLoS One 2011, 6:e22460.
169. Nishijima K., Ng Y.S., Zhong L., Bradley J., Schubert W., Jo N., Akita J., Samuelsson S.J., Robinson G.S., Adamis A.P., Shima D.T. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. Pathol. 2007, 171:53-67.
170. Nishikawa M., Mak J.C., Shirasaki H., Barnes P.J. Differential down-regulation of pulmonary beta 1- and beta 2-adrenoceptor messenger RNA with prolonged invivo infusion of isoprenaline. Eur. J. Pharmacol. 1993, 247:131-138.
171. Nyborg N.C., Prieto D., Benedito S., Nielsen P.J. Endothelin-1-induced contraction of bovine retinal small arteries is reversible and abolished by nitrendipine. Invest. Ophthalmol. Vis. Sci. 1991, 32:27-31.
172. O'Connor P., Kropf R.B., Dowling J.E. Catecholamine-sensitive adenylate cyclase in the white perch (Roccus americanus) retina: evidence for beta-adrenergic and dopamine receptors linked to adenylate cyclase. J.Neurochem. 1989, 53:969-975.
173. Ohira A., Wada Y., Fujii M., Nakamura M., Kasuya Y., Hamada Y., Shigenobu K. Effects of nipradilol (K-351) on alpha-adrenoceptor mediated responses in various isolated tissues. Arch. Int. Pharmacodyn. Ther. 1985, 278:61-71.
174. Oikawa F., Nakahara T., Akanuma K., Ueda K., Mori A., Sakamoto K., Ishii K. Protective effects of the beta3-adrenoceptor agonist CL316243 against N-methyl-D-aspartate-induced retinal neurotoxicity. Naunyn Schmiedeb. Arch. Pharmacol. 2012, 385:1077-1081.
175. Okamura T., Kitamura Y., Uchiyama M., Toda M., Ayajiki K., Toda N. Canine retinal arterial and arteriolar dilatation induced by nipradilol, a possible glaucoma therapeutic. Pharmacology 1996, 53:302-310.
176. Osborne N.N. Noradrenaline, a transmitter candidate in the retina. J.Neurochem. 1981, 36:17-27.
177. Osborne N.N., Casson R.J., Wood J.P.M., Chidlow G., Graham M., Melena J. Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog. Ret Eye Res. 2004, 23:91-147.
178. Osborne N.N., del Olmo-Aguado S. Maintenance of retinal ganglion cell mitochondrial functions as a neuroprotective strategy in glaucoma. Curr. Opin. Pharmacol. 2013, 13:16-22.
179. Osborne N.N., DeSantis L., Bae J.H., Ugarte M., Wood J.P., Nash M.S., Chidlow G. Topically applied betaxolol attenuates NMDA-induced toxicity to ganglion cells and the effects of ischaemia to the retina. Exp. Eye Res. 1999, 69:331-342.
180. Osborne N.N., Patel S. The presence of dopamine-β-hydroxylase-like enzyme in the vertebrate retina. Neurochem. Int. 1985, 7:51-56.
181. Otrock Z.K., Makarem J.A., Shamseddine A.I. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells. Mol. Dis. 2007, 38:258-268.
182. Panjala S.R., Jiang Y., Kern T.S., Thomas S.A., Steinle J.J. Increased tumor necrosis factor-alpha, cleaved caspase 3 levels and insulin receptor substrate-1 phosphorylation in the beta(1)-adrenergic receptor knockout mouse. Mol. Vis. 2011, 17:1822-1828.
183. Panjala S.R., Steinle J.J. Insulin and beta-adrenergic receptors inhibit retinal endothelial cell apoptosis through independent pathways. Neurochem. Res. 2011, 36:604-612.
184. Panjala S.R., Thomas S.A., Steinle J.J. Effects of insulin-like growth factor-1 (IGF-1) receptor signaling on rates of apoptosis in retina of dopamine beta hydroxylase (Dbh-/-) knockout mice. Auton. Neurosci. 2010, 152:21-26.
185. Park S.Y., Kang J.H., Jeong K.J., Lee J., Han J.W., Choi W.S., Kim Y.K., Kang J., Park C.G., Lee H.Y. Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1alpha protein-dependent mechanism. Int. J. Cancer 2011, 128:2306-2316.
186. Pascolini D., Mariotti S.P. Global estimates of visual impairment: 2010. Br. J. Ophthalmol. 2012, 96:614-618.
187. Patrizio M., Musumeci M., Piccone A., Raggi C., Mattei E., Marano G. Hormonal regulation of beta-myosin heavy chain expression in the mouse left ventricle. J.Endocrinol. 2013, 216:287-296.
188. Phipps J.A., Wilkinson-Berka J.L., Fletcher E.L. Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol. Invest. Ophthalmol. Vis. Sci. 2007, 48:927-934.
189. Pieh C., Kruger M., Lagreze W.A., Gimpel C., Buschbeck C., Zirrgiebel U., Agostini H.T. Plasma sE-selectin in premature infants: a possible surrogate marker of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2010, 51:3709-3713.
190. Pierce E.A., Avery R.L., Foley E.D., Aiello L.P., Smith L.E. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:905-909.
191. Poulaki V., Joussen A.M., Mitsiades N., Mitsiades C.S., Iliaki E.F., Adamis A.P. Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. Am. J. Pathol. 2004, 165:457-469.
192. Pradidarcheep W., Stallen J., Labruyère W.T., Dabhoiwala N.F., Michel M.C., Lamers W.H. Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors. Naunyn Schmiedeb. Arch. Pharmacol. 2009, 379:397-402.
193. Prinster S.C., Holmqvist T.G., Hall R.A. Alpha2C-adrenergic receptors exhibit enhanced surface expression and signaling upon association with beta2-adrenergic receptors. J.Pharmacol. Exp. Ther. 2006, 318:974-981.
194. Przewratil P., Sitkiewicz A., Andrzejewska E. Local serum levels of vascular endothelial growth factor in infantile hemangioma: intriguing mechanism of endothelial growth. Cytokine 2010, 49:141-147.
195. Quốc Lu'o'ng K.V., Nguyễn L.T. The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms. Cancer Manag. Res. 2012, 4:431-445.
196. Ray K., Dutta A., Panjwani U., Thakur L., Anand J.P., Kumar S. Hypobaric hypoxia modulates brain biogenic amines and disturbs sleep architecture. Neurochem. Int. 2011, 58:112-118.
197. Reiter E., Lefkowitz R.J. GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol. Metab. 2006, 17:159-165.
198. Ricci B., Calogero G., Caprilli A., Quaranta-Leoni F.M. Reduced severity of oxygen-induced retinopathy in the newborn rat after topical administration of timolol maleate. A preliminary study. Doc. Ophthalmol. 1991, 77:47-56.
199. Ricci B., Minicucci G., Manfredi A., Santo A. Oxygen-induced retinopathy in the newborn rat: effects of hyperbarism and topical administration of timolol maleate. Graefes Arch. Clin. Exp. Ophthalmol. 1995, 233:226-230.
200. Ricci B., Ricci F., Maggiano N. Oxygen-induced retinopathy in the newborn rat: morphological and immunohistological findings in animals treated with topical timolol maleate. Ophthalmologica 2000, 214:136-139.
201. Ristori C., Filippi L., Dal Monte M., Martini D., Cammalleri M., Fortunato P., la Marca G., Fiorini P., Bagnoli P. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. Invest. Ophthalmol. Vis. Sci. 2011, 52:155-170.
202. Robinson R., Barathi V.A., Chaurasia S.S., Wong T.Y., Kern T.S. Update on animal models of diabetic retinopathy: from molecular approaches to mice and higher mammals. Dis. Model Mech. 2012, 5:444-456.
203. Romano M.R., Biagioni F., Besozzi G., Carrizzo A., Vecchione C., Fornai F., Logranoa M.D. Effects of bevacizumab on neuronal viability of retinal ganglion cells in rats. Brain Res. 2012, 1478:55-63.
204. Rong P., Wilkinson-Berka J.L., Skinner S.L. Renin in thymus, gut, hindlimb, and adrenal of (mRen-2)27 and normal rats: secretion and content studies. Am. J. Physiol. 1999, 277:E639-E646.
205. Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., Kim R.Y. Ranibizumab for neovascular age-related macular degeneration. N.Engl. J. Med. 2006, 355:1419-1431.
206. Ruta L.M., Magliano D.J., Lemesurier R., Taylor H.R., Zimmet P.Z., Shaw J.E. Prevalence of diabetic retinopathy in Type 2 diabetes in developing and developed countries. Diabet. Med. 2013, 30:387-398.
207. Saint-Geniez M., Maharaj A.S., Walshe T.E., Tucker B.A., Sekiyama E., Kurihara T., Darland D.C., Young M.J., D'Amore P.A. Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLoS One 2008, 3:e3554.
208. Saishin Y., Takahashi K., Lima e Silva R., Hylton D., Rudge J.S., Wiegand S.J., Campochiaro P.A. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J.Cell. Physiol. 2003, 195:241-248.
209. Sakane N., Yoshida T., Yoshioka K., Nakamura Y., Umekawa T., Kogure A., Takakura Y., Kondo M. Beta 3-adrenoreceptor gene polymorphism: a newly identified risk factor for proliferative retinopathy in NIDDM patients. Diabetes 1997, 46:1633-1636.
210. Sans V., de la Roque E.D., Berge J., Grenier N., Boralevi F., Mazereeuw-Hautier J., Lipsker D., Dupuis E., Ezzedine K., Vergnes P., Taieb A., Leaute-Labreze C. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 2009, 124:e423-e431.
211. Schliebs R., Estrada E., Rothe T., Aurich M., Bigl V. Regional distribution of neurotransmitter receptors in the visual structures of the rat brain. Biomed. Biochim. Acta 1984, 43:1119-1125.
212. Seki M., Tanaka T., Sakai Y., Fukuchi T., Abe H., Nawa H., Takei N. Muller Cells as a source of brain-derived neurotrophic factor in the retina: noradrenaline upregulates brain-derived neurotrophic factor levels in cultured rat Muller cells. Neurochem. Res. 2005, 30:1163-1170.
213. Semenza G.L. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J.Appl. Physiol. (1985) 2000, 88:1474-1480.
214. Semkova I., Schilling M., Henrich-Noack P., Rami A., Krieglstein J. Clenbuterol protects mouse cerebral cortex and rat hippocampus from ischemic damage and attenuates glutamate neurotoxicity in cultured hippocampal neurons by induction of NGF. Brain Res. 1996, 717:44-54.
215. Setoguchi M., Ohya Y., Abe I., Fujishima M. Inhibitory action of betaxolol, a beta 1-selective adrenoceptor antagonist, on voltage-dependent calcium channels in guinea-pig artery and vein. Br. J. Pharmacol. 1995, 115:198-202.
216. Shamsi H.N., Masaud J.S., Ghazi N.G. Diabetic macular edema: new promising therapies. World J. Diabetes 2013, 4:324-338.
217. Shirasawa Y., Fujii M., Nakamura M. Venodilating action of nipradilol (K-351) in the pithed rat pretreated with dihydroergotamine. Jpn. J. Pharmacol. 1985, 39:77-82.
218. Shyu K.G., Liou J.Y., Wang B.W., Fang W.J., Chang H. Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. J.Biomed. Sci. 2005, 12:409-420.
219. Shyu K.G., Lu M.J., Chang H., Sun H.Y., Wang B.W., Kuan P. Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure. J.Card. Fail. 2005, 11:152-159.
220. Slomiany M.G., Rosenzweig S.A. Hypoxia-inducible factor-1-dependent and -independent regulation of insulin-like growth factor-1-stimulated vascular endothelial growth factor secretion. J.Pharmacol. Exp. Ther. 2006, 318:666-675.
221. Smith C.P., Sharma S., Steinle J.J. Age-related changes in sympathetic neurotransmission in rat retina and choroid. Exp. Eye Res. 2007, 84:75-81.
222. Smith L.E. IGF-1 and retinopathy of prematurity in the preterm infant. Biol. Neonate 2005, 88:237-244.
223. Smith L.E., Wesolowski E., McLellan A., Kostyk S.K., D'Amato R., Sullivan R., D'Amore P.A. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 1994, 35:101-111.
224. Sorriento D., Santulli G., Del Giudice C., Anastasio A., Trimarco B., Iaccarino G. Endothelial cells are able to synthesize and release catecholamines both invitro and invivo. Hypertension 2012, 60:129-136.
225. Sosula L., Beaumont P., Hollows F.C., Jonson K.M. Dilatation and endothelial proliferation of retinal capillaries in streptozotocin-diabetic rats: quantitative electron microscopy. Invest. Ophthalmol. 1972, 11:926-935.
226. Stahl A., Connor K.M., Sapieha P., Chen J., Dennison R.J., Krah N.M., Seaward M.R., Willett K.L., Aderman C.M., Guerin K.I., Hua J., Lofqvist C., Hellström A., Smith L.E. The mouse retina as an angiogenesis model. Invest. Ophthalmol. Vis. Sci. 2010, 51:2813-2826.
227. Steinle J.J. Sympathetic neurotransmission modulates expression of inflammatory markers in the rat retina. Exp. Eye Res. 2007, 84:118-125.
228. Steinle J.J., Booz G.W., Meininger C.J., Day J.N., Granger H.J. Beta 3-adrenergic receptors regulate retinal endothelial cell migration and proliferation. J.Biol. Chem. 2003, 278:20681-20686.
229. Steinle J.J., Chin V.C., Williams K.P., Panjala S.R. Beta-adrenergic receptor stimulation modulates iNOS protein levels through p38 and ERK1/2 signaling in human retinal endothelial cells. Exp. Eye Res. 2008, 87:30-34.
230. Steinle J.J., Cappocia F.C., Jiang Y. Beta-adrenergic receptor regulation of growth factor protein levels in human choroidal endothelial cells. Growth Factors 2008, 26:325-330.
231. Steinle J.J., Kern T.S., Thomas S.A., McFadyen-Ketchum L.S., Smith C.P. Increased basement membrane thickness, pericyte ghosts, and loss of retinal thickness and cells in dopamine beta hydroxylase knockout mice. Exp. Eye Res. 2009, 88:1014-1019.
232. Steinle J.J., Lindsay N.L., Lashbrook B.L. Cervical sympathectomy causes photoreceptor-specific cell death in the rat retina. Auton. Neurosci. 2005, 120:46-51.
233. Steinle J.J., Pierce J.D., Clancy R.L., P, G.S. Increased ocular blood vessel numbers and sizes following chronic sympathectomy in rat. Exp. Eye Res. 2002, 74:761-768.
234. Steinle J.J., Smith P.G. Role of adrenergic receptors in vascular remodelling of the rat choroid. Br. J. Pharmacol. 2002, 136:730-734.
235. Steinle J.J., Zamora D.O., Rosenbaum J.T., Granger H.J. Beta 3-adrenergic receptors mediate choroidal endothelial cell invasion, proliferation, and cell elongation. Exp. Eye Res. 2005, 80:83-91.
236. Stewart M.W. Anti-vascular endothelial growth factor drug treatment of diabetic macular edema: the evolution continues. Curr. Diabetes Rev. 2012, 8:237-246.
237. Sun Y., Dalal R., Gariano R.F. Cellular composition of the ridge in retinopathy of prematurity. Arch. Ophthalmol. 2010, 128:638-641.
238. Sun Y., Jin K., Xie L., Childs J., Mao X.O., Logvinova A., Greenberg D.A. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J.Clin. Invest. 2003, 111:1843-1851.
239. Tang J., Kern T.S. Inflammation in diabetic retinopathy. Prog. Retin. Eye Res. 2011, 30:343-358.
240. Tatsumi Y., Kanamori A., Nagai-Kusuhara A., Nakanishi Y., Agarwal N., Negi A., Nakamura M. Nipradilol protects rat retinal ganglion cells from apoptosis induced by serum deprivation invitro and by diabetes invivo. Curr. Eye Res. 2008, 33:683-692.
241. Thaker P.H., Han L.Y., Kamat A.A., Arevalo J.M., Takahashi R., Lu C., Jennings N.B., Armaiz-Pena G., Bankson J.A., Ravoori M., Merritt W.M., Lin Y.G., Mangala L.S., Kim T.J., Coleman R.L., Landen C.N., Li Y., Felix E., Sanguino A.M., Newman R.A., Lloyd M., Gershenson D.M., Kundra V., Lopez-Berestein G., Lutgendorf S.K., Cole S.W., Sood A.K. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat. Med. 2006, 12:939-944.
242. The Italian Medicine Agency Safety and Efficacy of Propranolol Eye Drops in Treating Retinopathy of Premature (DROP-PROP) 2013, Available at:, NLM identifier: NCT02014454. Last accessed (10.12.13.). http://clinicaltrials.gov/show/NCT02014454.
243. Tokunaga C.C., Mitton K.P., Dailey W., Massoll C., Roumayah K., Tarabishy N., Cheng M., Guzman E., Drenser K.A. Effect of anti-VEGF treatment on developing retina following oxygen-induced retinopathy. Invest. Ophthalmol. Vis. Sci. 2014, 55:1884-1892.
244. Tolosa L., Mir M., Asensio V.J., Olmos G., Llado J. Vascular endothelial growth factor protects spinal cord motoneurons against glutamate-induced excitotoxicity via phosphatidylinositol 3-kinase. J.Neurochem. 2008, 105:1080-1090.
245. Traver S., Salthun-Lassalle B., Marien M., Hirsch E.C., Colpaert F., Michel P.P. The neurotransmitter noradrenaline rescues septal cholinergic neurons in culture from degeneration caused by low-level oxidative stress. Mol. Pharmacol. 2005, 67:1882-1891.
246. Troadec J.D., Marien M., Darios F., Hartmann A., Ruberg M., Colpaert F., Michel P.P. Noradrenaline provides long-term protection to dopaminergic neurons by reducing oxidative stress. J.Neurochem. 2001, 79:200-210.
247. Uchida Y., Nakamura M., Shimizu S., Shirasawa Y., Fujii M. Vasoactive and beta-adrenoceptor blocking properties of 3,4-dihydro-8-(2-hydroxy-3-isopropylamino) propoxy-3-nitroxy-2H-1-benzopyran (K-351), a new antihypertensive agent. Arch. Int. Pharmacodyn. Ther. 1983, 262:132-149.
248. University of Wisconsin, Madison Propranolol for Diabetic Retinopathy 2012, Available at:, NLM Identifier: NCT01535495. Last accessed (10.12.13.). http://clinicaltrials.gov/show/NCT01535495.
249. Urenjak J., Obrenovitch T.P. Neuroprotection-rationale for pharmacological modulation of Na(+)-channels. Amino Acids 1998, 14:151-158.
250. Vazquez-Prado J., Casas-Gonzalez P., Garcia-Sainz J.A. Gprotein-coupled receptor cross-talk: pivotal roles of protein phosphorylation and protein-protein interactions. Cell. Signal 2003, 15:549-557.
251. Villarroel M., Ciudin A., Hernandez C., Simo R. Neurodegeneration: an early event of diabetic retinopathy. World J. Diabetes 2010, 1:57-64.
252. Virgili G., Parravano M., Menchini F., Brunetti M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst. Rev. 2012, 12:CD007419.
253. Vrydag W., Michel M.C. Tools to study beta3-adrenoceptors. Naunyn Schmiedeb. Arch. Pharmacol. 2007, 374:385-398.
254. Walker R.J., Anderson N.M., Jiang Y., Bahouth S., Steinle J.J. Role of beta-adrenergic receptor regulation of TNF-alpha and insulin signaling in retinal Muller cells. Invest. Ophthalmol. Vis. Sci. 2011, 52:9527-9533.
255. Walker R.J., Steinle J.J. Role of beta-adrenergic receptors in inflammatory marker expression in Muller cells. Invest. Ophthalmol. Vis. Sci. 2007, 48:5276-5281.
256. Wallukat G. The beta-adrenergic receptors. Herz 2002, 27:683-690.
257. 2 tension. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:5510-5514.
258. Wang G.L., Semenza G.L. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:4304-4308.
259. Wang S., Koster K.M., He Y., Zhou Q. miRNAs as potential therapeutic targets for age-related macular degeneration. Future Med. Chem. 2012, 4:277-287.
260. 2+)-mediated injury in myelinated CNS axons. Brain Res. 1994, 644:197-204.
261. West H., Richardson W.D., Fruttiger M. Stabilization of the retinal vascular network by reciprocal feedback between blood vessels and astrocytes. Development 2005, 132:1855-1862.
262. Wiley L.A., Berkowitz B.A., Steinle J.J. Superior cervical ganglionectomy induces changes in growth factor expression in the rat retina. Invest. Ophthalmol. Vis. Sci. 2006, 47:439-443.
263. Wiley L.A., Rupp G.R., Steinle J.J. Sympathetic innervation regulates basement membrane thickening and pericyte number in rat retina. Invest. Ophthalmol. Vis. Sci. 2005, 46:744-748.
264. Wilkinson-Berka J.L., Kelly D.J., Rong P., Campbell D.J., Skinner S.L. Characterisation of a thymic renin-angiotensin system in the transgenic m(Ren-2)27 rat. Mol. Cell. Endocrinol. 2002, 194:201-209.
265. Wilkinson-Berka J.L., Tan G., Jaworski K., Ninkovic S. Valsartan but not atenolol improves vascular pathology in diabetic Ren-2 rat retina. Am. J. Hypertens. 2007, 20:423-430.
266. Williams K.P., Steinle J.J. Maintenance of beta-adrenergic receptor signaling can reduce Fas signaling in human retinal endothelial cells. Exp. Eye Res. 2009, 89:448-455.
267. Witkovsky P. Dopamine and retinal function. Doc. Ophthalmol. 2004, 108:17-40.
268. Witmer A.N., Dai J., Weich H.A., Vrensen G.F., Schlingemann R.O. Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. J.Histochem. Cytochem. 2002, 50:767-777.
269. Witmer A.N., Vrensen G.F., Van Noorden C.J., Schlingemann R.O. Vascular endothelial growth factors and angiogenesis in eye disease. Prog. Retin. Eye Res. 2003, 22:1-29.
270. Wood J.P., DeSantis L., Chao H.M., Osborne N.N. Topically applied betaxolol attenuates ischaemia-induced effects to the rat retina and stimulates BDNF mRNA. Exp. Eye Res. 2001, 72:79-86.
271. Wood J.P., Schmidt K.G., Melena J., Chidlow G., Allmeier H., Osborne N.N. The beta-adrenoceptor antagonists metipranolol and timolol are retinal neuroprotectants: comparison with betaxolol. Exp. Eye Res. 2003, 76:505-516.
272. Wrzal P.K., Devost D., Petrin D., Goupil E., Iorio-Morin C., Laporte S.A., Zingg H.H., Hebert T.E. Allosteric interactions between the oxytocin receptor and the beta2-adrenergic receptor in the modulation of ERK1/2 activation are mediated by heterodimerization. Cell. Signal 2012, 24:342-350.
273. Wu H., Wei W., Song L., Zhang L., Chen Y., Hu X. Paeoniflorin induced immune tolerance of mesenteric lymph node lymphocytes via enhancing beta 2-adrenergic receptor desensitization in rats with adjuvant arthritis. Int. Immunopharmacol. 2007, 7:662-673.
274. Yang J., Liu Y., Fan X., Li Z., Cheng Y. A pathway and network review on beta-adrenoceptor signaling and beta blockers in cardiac remodeling. Heart Fail Rev. 2013, 10.1007/s10741-013-9417-4.
275. Yang E.V., Sood A.K., Chen M., Li Y., Eubank T.D., Marsh C.B., Jewell S., Flavahan N.A., Morrison C., Yeh P.E., Lemeshow S., Glaser R. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res. 2006, 66:10357-10364.
276. Ygawa Y., Aizawa N., Homma Y. Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder. Korean J. Urol. 2010, 51:811-818.
277. Zachary I. Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. Neurosignals 2005, 14:207-221.
278. Zarbin M.A., Wamsley J.K., Palacios J.M., Kuhar M.J. Autoradiographic localization of high affinity GABA, benzodiazepine, dopaminergic, adrenergic and muscarinic cholinergic receptors in the rat, monkey and human retina. Brain Res. 1986, 374:75-92.
279. Zechmeister-Koss I., Huic M. Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic review. Br. J. Ophthalmol. 2012, 96:167-178.
280. Zeng X.X., Ng Y.K., Ling E.A. Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Vis. Neurosci. 2000, 17:463-471.
281. Zhang Q., Guy K., Pagadala J., Jiang Y., Walker R.J., Liu L., Soderland C., Kern T.S., Ferry R., He H., Yates C.R., Miller D.D., Steinle J.J. Compound 49b prevents diabetes-induced apoptosis through increased IGFBP-3 levels. Invest. Ophthalmol. Vis. Sci. 2012, 53:3004-3013.
282. Zhang Q., Steinle J.J. DNA-PK phosphorylation of IGFBP-3 is required to prevent apoptosis in retinal endothelial cells cultured in high glucose. Invest. Ophthalmol. Vis. Sci. 2013, 54:3052-3057.
283. Zhang S.X., Sima J., Wang J.J., Shao C., Fant J., Ma J.X. Systemic and periocular deliveries of plasminogen kringle 5 reduce vascular leakage in rat models of oxygen-induced retinopathy and diabetes. Curr. Eye Res. 2005, 30:681-689.
284. Zheng Z., Chen H., Xu X., Li C., Gu Q. Effects of angiotensin-converting enzyme inhibitors and beta-adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathy. Exp. Eye Res. 2007, 84:745-752.
285. Zhu W.Z., Chakir K., Zhang S., Yang D., Lavoie C., Bouvier M., Hebert T.E., Lakatta E.G., Cheng H., Xiao R.P. Heterodimerization of beta1- and beta2-adrenergic receptor subtypes optimizes beta-adrenergic modulation of cardiac contractility. Circ. Res. 2005, 97:244-251.
286. Zink S., Rosen P., Lemoine H. Micro- and macrovascular endothelial cells in beta-adrenergic regulation of transendothelial permeability. Am. J. Physiol. 1995, 269:C1209-C1218.
287. Zschauer A.O., Davis E.B., Anderson D.R. Glaucoma, capillaries and pericytes. 4. Beta-adrenergic activation of cultured retinal pericytes. Ophthalmologica 1996, 210:276-279.